Clene Nanomedicine
Clene Nanomedicine is a biopharmaceutical company focused on developing nanotherapeutics for neurodegenerative diseases, with its lead candidate, CNM-Au8, targeting ALS, MS, and Parkinson's Disease.
Services
Clene Nanomedicine specializes in developing nanotherapeutics aimed at addressing cellular energy impairments prevalent in neurodegenerative diseases. The company has established an Expanded Access Program (EAP) to provide investigational medicines to patients who meet specific eligibility criteria. This initiative allows patients to access potentially life-altering treatments while they are still under evaluation in clinical trials.
Headquarters and Facilities
Clene Nanomedicine operates out of its headquarters located at 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah 84121. The company also maintains a manufacturing and research and development facility at 500 Principio Parkway West, Suite 400, North East, Maryland 21901. These locations support the development and manufacturing of Clene's innovative nanotherapeutics.
Lead Product: CNM-Au8
CNM-Au8 is Clene Nanomedicine's lead drug candidate, a suspension of gold nanocrystals developed as a disease-modifying treatment for neurodegenerative conditions such as ALS, multiple sclerosis (MS), and Parkinson's Disease. This innovative therapy is designed to improve cellular energy production and has shown promise in treating these debilitating conditions. Clinical trials to evaluate the efficacy of CNM-Au8 are actively ongoing, with multiple studies registered on clinicaltrials.gov.
Clinical Trials
Clene Nanomedicine is heavily involved in clinical research to validate the effectiveness of its lead product, CNM-Au8, for the treatment of ALS, MS, and Parkinson's Disease. Several clinical trials are in progress, and the details of these studies are registered on clinicaltrials.gov. These trials are critical in assessing the safety and therapeutic potential of CNM-Au8 and moving the product towards regulatory approval.
Research and Development
Clene Nanomedicine is advancing a pipeline of clean-surfaced, catalytically-active nanocrystals intended for therapeutic use. The R&D efforts focus on developing treatments that target cellular energy impairments, a common factor in neurodegenerative diseases. By leveraging these cutting-edge nanocrystal technologies, Clene aims to provide new treatment options for conditions that currently have limited therapeutic solutions.